6505--Baclofen Tablets (VA-25-00026620)
ID: 36E79725R0015Type: Solicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/21454b0cf66a4a8aaf2f4b88382279b4/view
Timeline
    Description

    The Department of Veterans Affairs is soliciting proposals for the supply of Baclofen Tablets under the solicitation titled "6505--Baclofen Tablets (VA-25-00026620)." The primary objective of this procurement is to establish a reliable source for various strengths of Baclofen tablets, ensuring consistent availability and quality at pre-negotiated prices, while complying with the Drug Supply Chain Security Act and Good Manufacturing Practices. This contract is crucial for maintaining the pharmaceutical needs of VA facilities, addressing issues such as compliance, backorders, and recalls. Interested offerors must submit their proposals by February 5, 2025, at 2:30 PM CST, and can direct inquiries to Contracting Officer Adrienne A Albachiara at Adrienne.Albachiara@va.gov.

    Point(s) of Contact
    Adrienne A AlbachiaraContracting Officer
    Adrienne.Albachiara@va.gov
    Files
    Title
    Posted
    36E79725R0015_1.docx
    The Department of Veterans Affairs (VA) plans to issue Request for Proposal (RFP) 36E79725R0015 for Baclofen Tablets, aimed at securing an uninterrupted supply for VA facilities, the Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). The contract will cover a one-year period with four additional pre-priced renewal options. Offerors must provide products labeled with their unique NDC numbers. The solicitation will be posted electronically on or around December 30, 2024, with a submission deadline of January 13, 2025. The estimated annual requirements detail various Baclofen tablet dosages and package sizes, indicating a high volume demand. The procurement process emphasizes continuous monitoring of updates via SAM.gov and restricts paper copies and phone requests. The primary point of contact for inquiries is Adrienne A. Albachiara, available via email. This presolicitation notice serves as a preliminary announcement to inform potential suppliers of upcoming procurement opportunities related to Baclofen Tablets to support multiple federal health initiatives.
    36E79725R0015.docx
    The document outlines a Request for Proposal (RFP) from the Department of Veterans Affairs (VA) seeking bids for the supply of Baclofen drug formulations through its Pharmaceutical Prime Vendor Program. The primary objective is to establish a reliable source for various Baclofen tablet strengths that ensures consistent availability and quality at pre-negotiated prices. Offerors must provide pricing for the base year and four one-year options while including a 0.5% Cost Recovery Fee in their bid. Important details include the requirement for an 11-digit National Drug Code (NDC) for each offered product, compliance with the Drug Supply Chain Security Act, and adherence to Good Manufacturing Practices as evaluated by the FDA. The awarded contractor must engage in business-to-business agreements with respective vendors. The contract covers a range of VA facilities and is designed to streamline procurement for necessary pharmaceuticals, addressing compliance, backorders, and recalls. Overall, this RFP establishes the framework for contracting pharmaceutical supplies, emphasizing the need for quality standards, pricing transparency, and the fulfillment of legal obligations for participating organizations.
    36E79725R0015 0001.docx
    The document outlines an amendment to Request for Proposal (RFP) 36E79725R0015 through the Department of Veterans Affairs (VA) regarding the procurement of Baclofen Tablets. The primary purpose of the amendment is to extend the deadline for offer submissions to February 5, 2025, at 2:30 PM CST. All interested offerors are instructed to submit their proposals to designated VA email addresses. The amendment signifies changes to previous solicitation timelines while ensuring that all terms and conditions remain in effect as specified in the referenced documents. Overall, this amendment serves to facilitate greater participation by extending the offer deadline while maintaining compliance with federal contracting procedures.
    Lifecycle
    Title
    Type
    6505--Baclofen Tablets (VA-25-00026620)
    Currently viewing
    Solicitation
    6505--Baclofen Tablets (VA-25-00026620)
    Presolicitation
    Similar Opportunities
    6505--Mycophenolate Mofetil RFP
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) numbered 36E79725R0010 for the procurement of Mycophenolate Mofetil tablets and capsules, intended for use by the VA, Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS). The procurement aims to secure a reliable source of supply for these essential medications, with a contract term of one year and the option to extend for four additional years, emphasizing the importance of uninterrupted access to critical pharmaceuticals for veterans and associated federal programs. Interested offerors must comply with specific packaging requirements, including child-resistant closures for smaller bottles, and are encouraged to check the designated URL for updates, with the solicitation expected to be issued around February 14, 2025, and offers accepted until February 28, 2025. For inquiries, potential bidders can contact Amber Zavala at amber.zavala@va.gov or by phone at (708) 786-5245.
    6505--Bevacizumab Injection
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) intends to procure Bevacizumab Injections through a Request for Proposal (RFP) designated as 36E79725R0019. This procurement aims to secure an uninterrupted supply of Bevacizumab, a critical pharmaceutical product used in the treatment of various medical conditions, for the VA, Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). The contract will span one year with four additional one-year option periods, and the estimated annual requirements include various package sizes of Bevacizumab, with a total estimated usage of over 100,000 vials. Interested offerors must submit their proposals by March 4, 2025, at 2:30 PM Central Time, and can direct inquiries to Contract Specialist Matthew Poulin at Matthew.Poulin@va.gov or by phone at 708-786-5186.
    6505--Tamsulosin Capsules
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for the procurement of Tamsulosin Hydrochloride capsules as part of its Pharmaceutical Prime Vendor (PPV) Programs. Offerors are required to submit pricing for a base year and four option years, ensuring compliance with FDA standards and providing a unique 11-digit National Drug Code (NDC) for each product. This procurement is vital for maintaining a consistent supply of necessary pharmaceuticals to federal healthcare facilities, adhering to regulatory standards while ensuring availability and pricing stability. Interested parties must submit their offers by February 24, 2025, at 2:30 PM CST, and can contact Contract Specialist Andrew J. Cazares at Andrew.Cazares@va.gov for further information.
    6505--Phenytoin SA Capsules (VA-25-00022318)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) intends to issue a Request for Proposal (RFP) for the procurement of Phenytoin Sodium Extended 100MG Sustained Action Capsules, designated as solicitation number 36E79725R0016. This unrestricted contract aims to ensure a reliable supply of these essential medications for the VA, Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS), with one contract awarded for an initial period of one year and the option for four additional one-year periods. The estimated annual requirement is approximately 16,653 units, highlighting the critical need for uninterrupted supply to support service members and associated organizations. Interested offerors should submit their proposals by March 7, 2025, following the electronic issuance of the RFP on or about February 21, 2025, and may direct inquiries to Contract Specialist Youlanda Duggar at youlanda.duggar@va.gov.
    6505--Fluticasone Propionate 50 MCG/Spray Soln, Nasal, 16GM
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Fluticasone Propionate 50 MCG/Spray solution, nasal, 16GM, intended for use by various federal agencies including the Department of Defense, Bureau of Prisons, and Indian Health Service. The objective of this procurement is to secure a reliable and uninterrupted supply of this medication for a contract period of one year, with the possibility of four additional one-year extensions. This medication is crucial for treating nasal conditions, and the estimated annual requirement is approximately 5,784,828 bottles. The solicitation will be available electronically on or around February 11, 2025, with a closing date set for February 25, 2025. Interested vendors should direct inquiries to Michael Olszewski at michael.olszewski@va.gov or call 708-786-4966.
    6505--Rituximab and Biosimilars
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) designated as 36E79725R0021 for the procurement of Rituximab and its biosimilars, aimed at ensuring a reliable supply for various federal entities, including the Department of Defense and the Bureau of Prisons. The contract will span one year with four additional one-year options, emphasizing the necessity of maintaining an uninterrupted supply chain for these critical medications. Offerors must provide the exact product names along with unique National Drug Codes (NDC), with estimated annual requirements of 17,858 vials of Rituximab 10mg/ml and 25,111 vials of the 50mg/ml variant. The solicitation is expected to be published around February 17, 2025, with a closing date around March 4, 2025; interested parties should direct inquiries to Deb Fassl at Deborah.Fassl@va.gov.
    6505--Domestic Pharmaceuticals/Med/Surge
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is conducting a Sources Sought notice to identify qualified domestic pharmaceutical manufacturers capable of supplying a range of medications for the Consolidated Mail Outpatient Pharmacy (CMOP). The procurement aims to ensure a reliable supply of domestically manufactured pharmaceuticals, including glucose test strips, hypertension treatments, and various other essential medications. This initiative is crucial for maintaining the health and well-being of veterans, as it supports ongoing healthcare needs. Interested manufacturers must submit their capability statements by February 5, 2025, to Josie Linaweaver at josie.linaweaver@va.gov, and are reminded to register in the System for Award Management (SAM) prior to contract award.
    6505--Diclofenac Sodium (NA) 1% Gel
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking to procure Diclofenac Sodium (NA) 1% Gel, a pharmaceutical product essential for pain management in patients. This presolicitation opportunity falls under the Pharmaceutical Preparation Manufacturing industry, specifically categorized under the NAICS code 325412 and PSC code 6505, indicating its relevance in the drugs and biologicals sector. The procurement aims to ensure the availability of this critical medication for veterans, highlighting its importance in providing effective treatment options. Interested vendors can reach out to Contract Specialist Ray Roldan at raymond.roldan@va.gov or call 708-786-4930 for further details regarding the solicitation process.
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    760-25-1-050-0154 -Leavenworth CMOP THYROID TABLETS -(VA-25-00022614)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for the procurement of Armour Thyroid tablets for the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP) under solicitation number 36C77025Q0079. This Request for Quotation (RFQ) emphasizes the need for specific brand-name pharmaceuticals, with a focus on compliance with federal regulations, including the Drug Supply Chain Security Act and the Buy American Act. The procurement process aims to ensure a reliable supply of essential medications for veterans, with a firm-fixed-price contract expected to be awarded based on fair market evaluations. Interested vendors must submit their quotes by December 27, 2024, at 4:00 PM CST, and can direct inquiries to Jennifer L. Knight at jennifer.knight@va.gov or by phone at 913-684-0162.